Molecular Partners AG (XSWX:MOLN)
CHF 3.305 -0.115 (-3.36%) Market Cap: 108.63 Mil Enterprise Value: -74.61 Mil PE Ratio: 0 PB Ratio: 0.62 GF Score: 53/100

Molecular Partners AG at TD Cowen Inc Radiopharmaceutical Innovation Summit (Virtual) Transcript

Jun 20, 2023 / 04:00PM GMT
Release Date Price: CHF5.8 (-0.85%)
Mike Nedelcovych
TD Cowen, Inc. - Analyst

Good afternoon, everyone. Welcome to the Molecular Partners session of Cowen's inaugural Radiopharmaceutical Innovation Summit. My name is Mike Nedelcovych. I'm one of the pharmaceutical analysts at TD Cowen. And I'm very pleased to welcome to the chat, Dr. Patrick Amstutz, who is CEO of Molecular Partners; as well as Dr. Danny Steiner, who is Senior Vice President of Research.

Patrick, Danny, thanks for joining us.

Patrick Amstutz
Molecular Partners AG - CEO, Member of the Management Board, Member of the Board of Directors

Thanks, Mike. Great for having us.

Danny Steiner
Molecular Partners AG - SVP Research

Thanks, Mike (multiple speakers)

Questions & Answers

Mike Nedelcovych
TD Cowen, Inc. - Analyst

Lovely. Let's start with first a broad question for investors who may not be so familiar with your company and your efforts. Can you give us first some background on your protein engineering platform? So what

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot